加载中…
Place · Level 3 · Condition
中国 1.4 亿患者 · IR 三通路 · DiRECT 46% 缓解 · HbA1c / OGTT 解读 · 饮食 + 运动 + 药物完整谱
synergy · 1
↔PCOS
Sex-hormone imbalance amplifies insulin resistance: higher androgens in PCOS worsen it, while resistance itself lowers SHBG and pushes free androgen up — a loop that turns on its own, which is why both sides need managing together.
depletes · 1
Metformin is first line, cheap, with decades of safety data, and one of its costs is that long-term use drags vitamin B12 down — the mechanism being interference with calcium-dependent uptake in the terminal ileum. Not a reason to stop it; a reason to monitor.
regulates · 11
High-GI / liquid fructose / low-fiber → postprandial glucose peaks + chronic hyperinsulinemia → hepatic-pancreatic lipid overload (Taylor twin cycle) → β-cell decline. DiRECT (Lean 2018 Lancet, N=298): 12-wk VLCD → 46% remission at 1 yr (86% with ≥15 kg loss).
Taylor twin cycle: NAFLD (hepatic TG >5%) → VLDL output ↑ → ectopic lipid deposition in pancreatic islets → β-cell decline → T2D. DiRECT reverses in this order: hepatic TG drops 30% in week 1, normalises by week 8; pancreatic TG normalises by week 12.
T2D + HTN share insulin resistance + endothelial dysfunction + sympathetic activation + RAAS upregulation. Clinical overlap: 75% of T2D patients have HTN; SPRINT subgroup T2D benefits from <120 SBP target. Two pillars of metabolic syndrome.
OSA → repeated nocturnal hypoxia + sympathetic surge + deep-sleep disruption → worsens insulin resistance + HbA1c. Reverse: T2D neuropathy + obesity → upper-airway collapse vulnerability. SURMOUNT-OSA (NEJM 2024) tirzepatide improves both in one move.
Muscle is the largest postprandial glucose sink (~80%); sarcopenia ↓ disposal → IR + HbA1c ↑. Reverse: T2D neuropathy + chronic inflammation + IGF-1 resistance accelerate sarcopenia. GLP-1 era demands protein + resistance training to avoid double deterioration.
Muscle contraction recruits GLUT4 via AMPK, insulin-independent. DPP 2002 NEJM: exercise + diet → T2D progression risk ↓58% (better than metformin). Reynolds 2016: post-meal 15-min walk → postprandial glucose ↓30%.
Oestrogen kept fat subcutaneous — the pear shape. Once it goes, fat redistributes to the abdomen and viscera, toward the apple. More visceral fat means more insulin resistance, and metabolic syndrome, type 2 diabetes and fatty liver follow.
Insulin is the key that lets glucose into cells, and insulin resistance is the cell going deaf to it: the body compensates by making more and more, until the beta-cell key factory wears out — and that is the moment type 2 diabetes begins.
Ectopic fat is the hand that breaks the lock: lipid accumulating where it should not, in muscle and liver, whose intermediates (DAG, ceramide) activate PKC-theta and JNK, which damage IRS-1. Fructose's de novo lipogenesis route sits upstream of that step.
Glucose control belongs in the baseline column of stroke prevention: chronic hyperglycaemia damages endothelium and small vessels, stacking onto the same pathway as blood pressure, lipids and smoking rather than opening a separate one.
For people managing chronic disease, walking is the lowest-threshold lever on blood sugar: no equipment, no sweat required — the contraction itself is what moves the glucose.
contrast · 1
Natural Ozempic is off by an order of magnitude: berberine takes off 2-5% of body weight, GLP-1 agonists 15-20%. At best it substitutes for metformin, not for a GLP-1 — and the two do not even share a pathway.
Two different pathways
Berberine acts on **AMPK** — the cell's master energy switch. In effect it **tricks that switch into believing the cell is running out of fuel**, flipping the body into spend-less, burn-more-glucose-and-fat mode. That is the route metformin's class takes. GLP-1 drugs take an entirely different one: the incretin receptor — glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central satiety signalling. **They share no pathway**, so 'the natural version of' is not a claim that can be made.
yin-2008-metabolismOrder of magnitude
Put the numbers side by side and the gap is not rhetorical: - Glycaemia: pooling 27 RCTs, berberine lowers HbA1c by about **0.7%** — roughly a starting dose of metformin - Weight: berberine **2-5%**, GLP-1 agonists **15-20%** At best, then, it substitutes for metformin — and on uneven evidence (most trials from China and India). Placed where a GLP-1 belongs, it is an order of magnitude short.
lan-2015-jepThe test
'The natural version of X' comes apart with a general two-question test, and this edge is its cleanest demonstration: 1. **Same pathway?** If not, there is no substitution — just two things that both lower glucose. 2. **How far apart in magnitude?** Same direction is not same tier: 2-5% and 15-20% are both weight loss, and they are not the same event. Only when both questions pass is 'substitute' the right word; passing only the second means same class, lower tier, and only the first means same route, less force.